Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.
Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.
As quoted in the press release:
The method of use claims secured in patent number 5192020 entitled “Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen” provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
Click here to read the full Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) press release.
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 1806.83 | -1.58 | |
| Silver | 19.86 | +0.01 | |
| Copper | 3.60 | -0.10 | |
| Palladium | 1956.00 | +11.00 | |
| Platinum | 887.11 | +1.10 | |
| Oil | 109.39 | +3.63 | |
| Heating Oil | 3.90 | +0.07 | |
| Natural Gas | 5.70 | +0.07 | |